Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
According to figures published Tuesday by the Swiss pharma industry association InterpharmaExternal link and the umbrella group for health insurers SantéSuisseExternal link, the difference in the price of patented drugs in Switzerland compared to elsewhere is 7%, down from 9% last year.
This is thanks in part to more favourable exchange rates, as well as regular price controls by the Federal Office of Public Health (FOPH), according to the groups. The savings due to lower prices are estimated to be some CHF325 million ($323 million).
However, it’s a different story for generic drugs, which are twice as expensive in Switzerland than in similar markets. The Swiss also tend to buy less generics, which represent 23% of volume and 18% of sales. In the United Kingdom, as a comparison, generics represent 85% of volume and 38% of sales.
For example, in Switzerland a pack of the patented painkiller Dafalgan costs CHF6.95 more than the generic version Paracetamol. Despite the potential savings, Dafalgan remains more popular: 900,000 packages were sold last year for a total of CHF23.1 million, compared to only 65,000 packs of Paracetamol sold at CHF1.2 million.
Despite the discrepancies, buying generics still represent savings compared to patented versions, SantéSuisse says.
This is the tenth edition of the report, which compares prices for 250 of the best-selling drugs in Switzerland to those in Belgium, Denmark, Germany, Finland, France, Great Britain, the Netherlands, Austria and Sweden.
Related Stories
Popular Stories
More
Demographics
Roger Federer is not eternal, but he changed tennis forever
Switzerland could produce up to 5Mt of emissions annually by 2050
This content was published on
Two to five megatonnes of CO2 equivalents per year: this is the amount of greenhouse gas emissions that Switzerland is still expected to produce annually in 2050, a new study shows.
US tariffs putting 100,000 jobs at risk in Switzerland
This content was published on
US tariffs of 39% on Swiss imports will directly affect 100,000 jobs, mainly in the watchmaking, machinery, metals, and food industries, economiesuisse warns.
This content was published on
Switzerland has released CHF4 million (nearly $5 million) to help Sudan, which has been severely affected by famine and cholera.
Switzerland rejects new Israeli settlements in Palestinian territory
This content was published on
Switzerland says it rejects the announced construction of thousands of housing units in the Israeli-occupied Palestinian West Bank.
Larry Finck and André Hoffmann named interim co-chairs of WEF board
This content was published on
The WEF also revealed an investigation commissioned by the board has cleared its founder Klaus Schwab and his wife of accusations made by anonymous whistleblowers.
Vice-president of German parliament in favour of Switzerland joining EU
This content was published on
The vice-president of the Bundestag says his country should support closer ties between Switzerland and the European Union given the customs conflict with the United States.
Lindt & Sprüngli reportedly considering shifting Easter bunny production to US
This content was published on
Swiss chocolate manufacturer Lindt & Sprüngli could relocate the production of its gold-wrapped Easter bunnies to the US in order to circumvent the import tariffs imposed by the Trump administration.
Swiss petition launched against curbing 30km/h speed limit
This content was published on
The Traffic Club of Switzerland (TCS) has submitted a petition to the Federal Chancellery, challenging the 30km/h speed limit on local roads.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Costs of generic drugs and outpatient services targeted
This content was published on
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
This content was published on
Switzerland could save millions of francs by prescribing low-priced biotech drug copies, known as biosimilars, instead of expensive biologicals.
Swiss bend rules to provide patients with affordable treatment
This content was published on
Despite being a global hub for pharma companies, Switzerland is going to extraordinary lengths to source cheap generic drugs for Hepatitis C patients.
Generic drugs in Switzerland cost twice as much as in Europe
This content was published on
The price of generic drugs in Switzerland in 2017 was 52% higher than the average of nine other European countries, says a study.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.